Latest Conference Articles

Patients with non–small cell lung cancer (NSCLC) had an objective response rate of about 77%.

Scott Tagawa, MD, professor of medicine and urology at Weill Cornell Medicine, discusses safety and tolerability findings observed to date, renal and hematologic considerations, and the role of pharmacists.

New findings reveal lorundrostat significantly lowers blood pressure and albuminuria in patients with chronic kidney disease, enhancing standard treatment efficacy.

New research reveals similar severe outcomes for adults hospitalized with hMPV and RSV, emphasizing the need for awareness of both infections.

Pharmacists enhance LDL cholesterol management with tailored solutions like enlicitide, improving patient adherence and outcomes in cardiovascular care.

Giredestrant and everolimus show significant survival benefits for ER-positive, HER2-negative advanced breast cancer post-CDK4/6 therapy.

Discover how objective activity monitoring with accelerometers transforms cardiovascular risk assessment and treatment evaluation, enhancing patient care for pharmacists.

Expert highlights the benefits of early combination therapy in hypertension management, emphasizing improved blood pressure control and reduced side effects.

New research highlights the benefits of combining lutetium PSMA 617 with standard treatments, showing improved outcomes for prostate cancer patients.

Boehringer Ingelheim showcases its commitment to cardio-kidney-metabolic research, highlighting innovative therapies and advancements at AHA 2025.

Discover how emerging therapies in cardio-kidney-metabolic health reshape disease management at AHA 2025, highlighting interconnected health pathways.

Integrating a pharmacist into multidisciplinary settings allowed for more thorough low-density lipoprotein cholesterol lowering in unique settings.

A new wrist-worn accelerometer device effectively monitors activity levels in heart failure patients, revealing critical insights into cardiovascular health.

Inclisiran significantly enhances LDL-C goal attainment in post-acute coronary syndrome patients, improving lipid management outcomes.

New data from AHA 2025 demonstrate the benefits of pharmacist-led hypertension management in reducing hemoglobin A1c (HbA1c) and blood pressure in minority patients with type 2 diabetes.

Explore the critical role of pharmacists in improving cardiovascular health and addressing mortality trends in underserved communities.

A new drug, DR10624, shows promise in reducing triglycerides and liver fat, offering hope for patients with severe hypertriglyceridemia and fatty liver disease.

Shoa Clarke, MD, PhD, discusses the need for improved cholesterol testing and treatment in young adults, emphasizing the vital role of primary care teams and pharmacists in early intervention and adherence.

Explore the link between chronic kidney disease and cardiovascular risk, highlighting the importance of GFR and albuminuria in patient care.

Explore the need for integrated approaches in cardiovascular and kidney health to combat rising mortality rates and improve patient outcomes.

Experts at AHA 2025 advocate for integrated care in T2D and CKD, emphasizing cardiovascular risk management to enhance patient outcomes.

Discover how Sotatercept impacts cardiovascular health and its potential benefits for patients with pulmonary arterial hypertension (PAH) in this insightful article.

Pharmacists play a vital role in managing cardiovascular health, addressing medication adherence, and educating patients, said Zia Ul Haq, MPH, MBBS.

SGLT2 inhibitors significantly reduce atrial fibrillation risk and improve heart failure outcomes, outperforming GLP-1 agonists in cardiovascular benefits.

SHR-A1811 shows significant antitumor activity in early-stage HER2+ breast cancer, both alone and with pyrotinib, promising improved treatment outcomes.

Gedatolisib shows promise in enhancing progression-free survival for HR+/HER2– breast cancer patients resistant to standard therapies, as revealed in ESMO 2025.

Multiplex respiratory virus testing enhances clinical decision-making for RSV in community hospitals.